Phialogics AG has announced the appointment of Prof. Dr. Erich Schlick as Chairman of its Board of Directors.
Erich was introduced to Phialogics by BaseLaunch in 2022 and he has been supporting the startup first as a consultant and now as Chairman of the Board.
He is a Medical Doctor and Professor of Immunopharmacology. Before joining Phialogics he was a General Partner at Wellington Partners, the former Deputy Head of 3i Healthcare Worldwide, and a former member of the BASF Pharma Board with responsibility for research and development of Humira.
Andreas Ernst, Phialogics Chief Executive Officer, says: “We are really looking forward to working with Erich and benefitting from his broad experience and knowledge. Phialogics is a preclinical biotech company specialized in engineering next-generation biologics to rebalance the immune response in acute and chronic inflammation. Erich’s appointment will help strengthen the relationships with the biotech ecosystem and investment community. Phialogics will also benefit from his large, successful, and proven experience in drug development. After receiving pre-seed financing from BaseLaunch and HTGF, having Erich with us is a strategic move for our company to bring new solutions to patients with immunological diseases who need better treatment options.”
Erich Schlick says: “I am excited to join the startup company Phialogics AG as chairman of its board of directors because the company’s technology platform and its lead product offer new avenues for the treatment of serious immune disorders. I look forward to working with the founders of Phialogics and its team to further advance the technology and move the lead product into formal development.”
Phialogics is an innovative start-up in the field of autoimmune diseases. Founded in 2021 by a team of widely recognized experts in protein engineering and immunology, the company based in Basel (CH) and Heidelberg (GER) is committed to making a decisive contribution to the autoimmune disease space. The founding team is backed by strong Scientific Advisory and Supervisory Boards, which puts the company in a good position to move fast on the lead candidate and develop novel biologics.